MMMarc Massetti

Marc Massetti

*This is an algorithmically generated author record based on publicly available information.

Marc Massetti has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term socioeconomic, psychiatric, and societal burden in patients with grade 2 mIDH glioma and partner spillover burden, worsening with disease progression and RT/CT initiation

    by Jane Skjøth-Rasmussen, Slávka Lukacova, Morten Riisberg Johnsen, Céline Aubin, Anaïs Ragon, Marc Massetti, Oskar Ström, Aida Muhic

  • Open Access

    Evaluating work activity and societal burden in patients with grade 2 IDH-mutant glioma

    by Slávka Lukacova, Aida Muhic, Oskar Ström, Morten Johnsen, Céline Aubin, Marc Massetti, Jane Skjøth-Rasmussen

    Background: IDH-mutant (mIDH) gliomas affect relatively young and otherwise healthy patients with high workforce participation. Management typically involves surgery, radiotherapy, and/or chemotherapy (RT/CT), although immediate post-surgery treatment may be deferred in favor of active observation (AO) to preserve functioning. This study aimed to evaluate how disease progression and treatments impact work activity, medical and societal costs, and overall survival (OS) in grade 2 mIDH glioma patients initially managed with AO. Methods: This retrospective longitudinal study utilized Danish administrative registries. Patients with mIDH gliomas initially managed with AO between 2010 and 2022 were included. Employment rates, sick leaves, treatment patterns, medical resources and costs, and OS were examined from diagnosis to the end of follow-up or death. Results: Data from 237 patients were analyzed; 72.9% were alive at 10 years. After surgical recovery, ability to work was most impaired during RT/CT, necessitating nearly full-time sick leave. Work activity continuously decreased after each RT/CT treatment. Employment rates were similarly affected, from under 20% unemployment at baseline and during AO, up to 41% and 59% after first and second RT/CT. Similar trends were observed for medical resources and costs, and productivity losses. Conclusions: Patients with grade 2 mIDH glioma remain active at work after initial surgery when managed with AO. Work impairment increases over successive RT/CT courses, highlighting the need to preserve quality of life by integrating work ability into clinical practice and by developing new treatment strategies to delay aggressive therapies and avoid substantial medical and productivity costs.


  • EPH47 Modeling the Impact of the Vaccine Candidate TAK-003 on the Incidence of Dengue in French Overseas Territories

    by A. Nucit, R. Moreau, M. Massetti, C. Strub, E. Kharitonova, A. Tytula, J. Zawieja, H. Leleu, J. Shen

  • Open Access

    Organised screening for cervical cancer in France: a cost-effectiveness assessment

    by Stéphanie Barré, Marc Massetti, Henri Leleu, Frédéric De Bels

    Objective According to the third cancer plan, organised screening (OS) of cervical cancer (CC) among women aged 25–65 years should be implemented in France in the forthcoming years. The most efficient way to implement OS in the French healthcare system is yet to be determined. Methods A microsimulation model was developed adopting a collective ‘all payers’ perspective. A closed cohort of women eligible for CC screening and representative in terms of age and participation in individual screening (IndScr) by annual Papanicolaou (Pap) testing every 3 years was modelled on a lifetime horizon. Different OS strategies, additive to IndScr with a 61.9% participation rate based on mailed invitations to non-participant women to perform OS were assessed. Similar modalities were applied to OS and IndScr participants. Strategies implied different screening tests (Papanicolaou (Pap) test, human papillomavirus (HPV) test and p16/Ki67 double staining) and OS periodicity. Results Compared with IndScr only, all OS strategies were associated with decreased cancer incidence/mortality (from 14.2%/13.5% to 22.9%/25.8%). Most strategies generated extra costs ranging from €37.9 to €1607 per eligible woman. HPV testing every 10 and 5 years were cost saving. HPV tests every 10 and 5 years were the most efficient strategies, generating more survival at lower costs than Pap-based strategies. Compared to IndScr only, an HPV test every 10 years was cost saving. The most effective strategies were p16/Ki67 as primary or HPV positive confirmation tests, with respective incremental cost-effectiveness ratios of €6 541 250 and €101 391 per life year. Pap-based strategies generated intermediary results. Conclusion OS strategies based on the HPV test appear highly efficient. However, our results rely on the assumption that women and practitioners comply with the recommended OS periodicities (3, 5, 10 years). Implementing these OS modalities will require major adaptations to the current CC screening organisation. Pap test-based strategies might be simpler to setup while preparing an appropriate implementation of more efficient OS screening modalities.